Related Experiment Videos
Gamma hydroxybutyrate is not a GABA agonist
1American Institute of Biotechnology, Department of Research and Development, Elk Grove Village, IL 60007, USA.
Progress in Neurobiology
|September 1, 1996
Summary
Gamma hydroxybutyrate (GHB) is not a GABA agonist or prodrug, despite common assumptions. Research indicates GHB acts distinctly from gamma-aminobutyric acid (GABA) and does not significantly affect GABA receptors.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Gamma hydroxybutyrate (GHB) is widely recognized for inhibiting central dopamine (DA) release.
- GHB is commonly presumed to be a gamma-aminobutyric acid (GABA) agonist or prodrug.
- The central effects of GHB have been historically attributed to its interaction with GABA receptors.
Purpose of the Study:
- To critically evaluate the evidence supporting GHB's role as a GABA agonist or prodrug.
- To investigate the relationship between GHB, GABA, and GABA receptors.
- To differentiate the neurochemical and behavioral actions of GHB from GABA.
Main Methods:
- Review of existing biochemical, physiological, and behavioral studies on GHB and GABA.
- Analysis of GHB's effects on GABAergic responses.
- Assessment of GHB's interaction with GABAA and GABAB receptors at various concentrations.
Main Results:
- Evidence suggests GHB formation can be independent of GABA pathways.
- GHB exhibits distinct behavioral, biochemical, and physiological profiles compared to GABA.
- GHB does not consistently modulate responses induced by GABAA or GABAB agonists and shows minimal interaction with these receptors at sub-millimolar concentrations.
Conclusions:
- GHB is unlikely to function as a GABA prodrug or a direct GABA agonist.
- The neurobiological actions of GHB are distinct from those of GABA.
- The metabolite gamma butyrolactone (GBL) may exhibit some limited GABA agonist activity.